Redeye briefly comments on MedCap releasing preliminary Q4 2024 figures, significantly undershooting our estimates, especially at the EBITA level. The company cites weaker figures in Specialty Pharma as the most significant contributor to soft fourth-quarter profit. We expected weaker figures than in Q4 2023 for Specialty Pharma, but our estimates still turned out to be overly optimistic. Overall, we do not expect the profit warning to significantly change our long-term view of MedCap’s investment case.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se